- Home
- SENEA vs XNCR Comparison
SENEA vs XNCR Comparison
Compare SENEA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- XNCR
- Stock Information
- Founded
- SENEA 1949
- XNCR 1997
- Country
- SENEA United States
- XNCR United States
- Employees
- SENEA N/A
- XNCR N/A
- Industry
- SENEA Packaged Foods
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- XNCR Health Care
- Exchange
- SENEA Nasdaq
- XNCR Nasdaq
- Market Cap
- SENEA 629.3M
- XNCR 579.3M
- IPO Year
- SENEA N/A
- XNCR 2013
- Fundamental
- Price
- SENEA $103.20
- XNCR $8.23
- Analyst Decision
- SENEA
- XNCR Buy
- Analyst Count
- SENEA 0
- XNCR 7
- Target Price
- SENEA N/A
- XNCR $27.50
- AVG Volume (30 Days)
- SENEA 124.1K
- XNCR 788.6K
- Earning Date
- SENEA 06-12-2025
- XNCR 08-04-2025
- Dividend Yield
- SENEA N/A
- XNCR N/A
- EPS Growth
- SENEA N/A
- XNCR N/A
- EPS
- SENEA 5.90
- XNCR N/A
- Revenue
- SENEA $1,578,887,000.00
- XNCR $127,228,000.00
- Revenue This Year
- SENEA N/A
- XNCR N/A
- Revenue Next Year
- SENEA N/A
- XNCR $28.84
- P/E Ratio
- SENEA $17.19
- XNCR N/A
- Revenue Growth
- SENEA 8.25
- XNCR N/A
- 52 Week Low
- SENEA $56.36
- XNCR $7.16
- 52 Week High
- SENEA $104.59
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- SENEA 72.17
- XNCR 44.21
- Support Level
- SENEA $98.53
- XNCR $7.65
- Resistance Level
- SENEA $104.67
- XNCR $8.41
- Average True Range (ATR)
- SENEA 3.31
- XNCR 0.50
- MACD
- SENEA 1.16
- XNCR -0.06
- Stochastic Oscillator
- SENEA 92.45
- XNCR 29.74
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.